Report Overview

The Australian Duchenne Muscular Dystrophy Therapeutics Market size stood at around USD XX billion in 2020 and is projected to reach USD xx billion by 2028, exhibiting a CAGR of xx% during the forecast period.

Duchenne muscular dystrophy, or DMD, is a debilitating genetic condition that causes a gradual loss of muscle function that affects everyday movements and activities. Muscular dystrophyis a condition that causes progressive wasting of the muscles. Duchenne muscular dystrophy is a particular type of muscular dystrophy caused by a mutation in the DMD gene. It affects more boys than girls. The DMD gene helps produce a protein called dystrophin, which is important for muscle strength, support and repair. People with Duchenne muscular dystrophy dont produce the normal form of dystrophin, which means their muscles are more easily damaged and dont work properly. The genetic mutation of the DMD gene is either inherited from parents or caused by a genetic change in the child. This is the most common type affecting children. Its caused by a genetic fault on the X chromosome and mainly affects boys because males only have one X chromosome. Females have two X chromosomes, so may carry the defective gene without showing any symptoms.

The introduction of innovative medicines and treatments, disease-modifying therapies, and significant backing from various businesses for drug research are major driving drivers in the Duchenne Muscular Dystrophy market. Furthermore, mutation-specific treatments are expected to be a big advance in the treatment of Duchenne muscular dystrophy.



Market Drivers

Major driving factors in the Duchenne Muscular Dystrophy market are the introduction of novel drugs and therapies, disease-modifying therapies, strong support from various companies for drug development. Moreover, mutation-specific therapies are likely to emerge as a major breakthrough in the Duchenne muscular dystrophy treatment. Drug developers are also focusing on developing new drugs and therapies targeting newborns, young infants and also the last-stage DMD patients. In the last few years, there has been rapid development in the Duchenne Muscular Dystrophy Therapeutics.

However, there is still a large number of patients who are not able to benefit from therapies and drugs due to its high cost and lack of awareness.